We got news from AstraZeneca and Oxford University about their coronavirus vaccine candidate.
The data looks promising from the early stage trial of a key coronavirus vaccine study Monday in London that could lead to its broader use before the end of the year.
The details, published in the U.K. medical journal The Lancet, showed what the two groups described as humoral and cellular immune responses in human trials, with an acceptable safety profile. The study also showed 'potent' cellular and humoral immunogenicity in all 1,077 participants in the Phase 1/Phase II study.
“The immune responses observed following vaccination are in line with what we expect will be associated with protection against the SARS-CoV-2 virus, although we must continue with our rigorous clinical trial program to confirm this,” said Andrew Pollard, chief investigator of the Oxford Vaccine Trial at Oxford University and co-author of the trial.
"The interim Phase I/II data for our coronavirus vaccine shows that the vaccine did not lead to any unexpected reactions and had a similar safety profile to previous vaccines of this type," said Pollard.
"We saw the strongest immune response in participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination," he added.
Despite the newest vaccine optimism, Jim Cramer said one problem isn't going away even when a vaccine is developed and approved. Watch the video above for more.